Noom Med Reviews Metformin
Present in the formulary but not a meaningful gate. Noom's model does not depend on routing members through it before incretin therapy.
Sold as Glucophage · Reviewed September 19, 2026
What “Adjunct” means here
Available and used, but not the centre of the protocol — typically alongside or after another agent.
The pairing
How Noom Med handles Metformin
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Adjunct
- Gating
- Clinical indication only.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- No
- Titration protocol
- Asynchronous-first with NP review; synchronous visits available on request
- Off-ramp
- Behavioral maintenance track carried over from the consumer product
- Care team
- Nurse practitioners, Physician oversight, Behavioral coaches
Ask Noom Med this
What percentage of your members are maintained on metformin without escalating? If you cannot produce the number, it is not a cost control.
Watch out
High enrollment is a cost risk, not just a win. Model what happens if uptake lands at the top of Noom's range.
The molecule
Metformin in one page
Not a GLP-1, and not a weight-loss drug — but the first rung of nearly every credible step-therapy protocol, and effectively free. How a vendor uses metformin tells you whether its cost discipline is real.
Clinical profile
- Drug class
- Biguanide
- Brand names
- Glucophage — Type 2 diabetes
- Mechanism
- Reduces hepatic glucose production and improves insulin sensitivity. Weight effect is modest and secondary to the glycemic effect.
- Administration
- Oral, daily, usually with an extended-release formulation to improve tolerability.
- Titration
- Gradual escalation over several weeks, primarily to manage gastrointestinal tolerability.
- Typical result
- Modest weight reduction — typically low single digits as a percentage — alongside meaningful glycemic improvement in appropriate patients.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects, substantially reduced by extended-release formulations
- Long-term B12 depletion warranting periodic monitoring
- Lactic acidosis, rare and largely confined to renal impairment
What benefits teams need to know
A useful test of vendor honesty
Every vendor lists metformin. Far fewer can show you what share of their population is maintained on it without escalating. Ask for that number — it separates vendors with a step-therapy protocol from vendors with a step-therapy slide.
It does not compete with GLP-1s on weight
Metformin is not an alternative to incretin therapy for a member who needs substantial reduction. Its role is identifying the members who never needed the expensive drug, not substituting for it in those who do.
Alternatives
Other vendors and Metformin
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Virta Health Metabolic specialist | First-line | 8.7 | $40–$95 |
| Form Health Full-service clinical | Adjunct | 8.0 | $58–$105 |
| Twin Health Metabolic specialist | First-line | 7.8 | $55–$120 |
| Found Full-service clinical | First-line | 7.6 | $45–$85 |
| Vida Health Full-service clinical | First-line | 7.5 | $38–$78 |
| Teladoc Health Navigation & orchestration | First-line | 7.4 | $18–$44 |
Same vendor
Noom Med across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
First-line, with asynchronous-first intake and nurse-practitioner review. The low-friction pathway that drives Noom's category-leading enrollment also removes most of the brakes on initiation.
Available first-line on the same asynchronous pathway as semaglutide. Given tirzepatide's efficacy advantage, expect member preference to pull volume here once it is offered without a cost hierarchy.